NCT01301794View on ClinicalTrials.gov

Lovaza Mechanisms of Action

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2014

Conditions
Moderate Hypertriglyceridemia.
Interventions
DIETARY_SUPPLEMENT

Omega 3 fatty acid (Lovaza)

Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT01301794 - Lovaza Mechanisms of Action | Biotech Hunter | Biotech Hunter